Advertisement
TLPH vs TXMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TLPH is a Hold and TXMD is a Hold.
TLPH's RSI Indicator recovers from oversold territory
The RSI Indicator for TLPH moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 24 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for TLPH just turned positive on October 20, 2026. Looking at past instances where TLPH's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLPH advanced for three days, in 179 of 223 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
TLPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLPH as a result. In 80 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLPH entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. TLPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.783) is normal, around the industry mean (10.407). P/E Ratio (-4.565) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
TXMD in -3.63% downward trend, declining for three consecutive days on October 19, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TXMD declined for three days, in 271 of 311 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXMD as a result. In 92 of 110 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
TXMD moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TXMD crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.
The 50-day moving average for TXMD moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for TXMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TXMD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 76 cases where TXMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXMD advanced for three days, in 145 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
TXMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.789) is normal, around the industry mean (10.407). P/E Ratio (-92.500) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (7.740) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. TXMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
TLPH | TXMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 91 | |
PRICE GROWTH RATING 1..100 | 58 | 55 | |
P/E GROWTH RATING 1..100 | 21 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TXMD's Valuation (5) in the Pharmaceuticals Generic industry is significantly better than the same rating for TLPH (93) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew significantly faster than TLPH’s over the last 12 months.
TXMD's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as TLPH (100) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to TLPH’s over the last 12 months.
TXMD's SMR Rating (91) in the Pharmaceuticals Generic industry is in the same range as TLPH (99) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to TLPH’s over the last 12 months.
TXMD's Price Growth Rating (55) in the Pharmaceuticals Generic industry is in the same range as TLPH (58) in the Pharmaceuticals Other industry. This means that TXMD’s stock grew similarly to TLPH’s over the last 12 months.
TLPH's P/E Growth Rating (21) in the Pharmaceuticals Other industry is significantly better than the same rating for TXMD (98) in the Pharmaceuticals Generic industry. This means that TLPH’s stock grew significantly faster than TXMD’s over the last 12 months.
| TLPH | TXMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 90% | N/A |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Advances ODDS (%) | 7 days ago 80% | 2 days ago 71% |
| Declines ODDS (%) | 9 days ago 90% | 4 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TLPH’s FA Score shows that 1 FA rating(s) are green while TXMD’s FA Score has 1 green FA rating(s).
- TLPH’s FA Score: 1 green, 4 red.
- TXMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TLPH’s TA Score shows that 6 TA indicator(s) are bullish while TXMD’s TA Score has 4 bullish TA indicator(s).
- TLPH’s TA Score: 6 bullish, 2 bearish.
- TXMD’s TA Score: 4 bullish, 6 bearish.
Price Growth
TLPH (@Pharmaceuticals: Generic) experienced а +0.94% price change this week, while TXMD (@Pharmaceuticals: Generic) price change was -3.55% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
TLPH is expected to report earnings on Nov 11, 2026.
TXMD is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
TLPH and
Correlation & Price change
A.I.dvisor tells us that TLPH and TKNO have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPH and TKNO's prices will move in lockstep.
| Ticker / NAME | Correlation To TLPH | 1D Price Change % | ||
|---|---|---|---|---|
| TLPH | 100% | -1.87% | ||
| TKNO - TLPH | 24% Poorly correlated | +5.13% | ||
| HROW - TLPH | 24% Poorly correlated | -0.32% | ||
| AYTU - TLPH | 23% Poorly correlated | +1.02% | ||
| TXMD - TLPH | 21% Poorly correlated | -2.63% | ||
| ZSTK - TLPH | 21% Poorly correlated | -5.88% | ||
More | ||||
TXMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, TXMD has been loosely correlated with LIEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TXMD jumps, then LIEN could also see price increases.
| Ticker / NAME | Correlation To TXMD | 1D Price Change % | ||
|---|---|---|---|---|
| TXMD | 100% | -2.63% | ||
| LIEN - TXMD | 36% Loosely correlated | -0.11% | ||
| IMCC - TXMD | 24% Poorly correlated | -22.29% | ||
| ACB - TXMD | 23% Poorly correlated | +0.25% | ||
| BCRX - TXMD | 22% Poorly correlated | +0.39% | ||
| SBFM - TXMD | 22% Poorly correlated | -22.47% | ||
More | ||||